Regencell Bioscience (RGC) Fundamental Analysis: Revenue, Earnings & Valuation

0.62 / 10

Underperform

Fundamental rating is Underperform with a 0.6/10 score. Inventory turnover (106.6) and interest coverage (34.9) are decent, but revenue growth (134.7% YoY) and fixed‑asset turnover are poor, leading to a prudent stance.

Analysis Checks(4/7)

Total operating revenue (YoY growth rate %)

Value134.75

Score0/3

Weight50.54%

1M Return-2.75%

Inventory turnover ratio

Value106.57

Score3/3

Weight13.37%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score3/3

Weight-48.43%

1M Return2.33%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight30.09%

1M Return-1.54%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight24.81%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight14.94%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight14.67%

1M Return-0.74%

Is RGC undervalued or overvalued?

RGC scores 0.62/10 on fundamentals and holds a Premium valuation at present. Backed by its -54.81% ROE, 0.00% net margin, -3104.44 P/E ratio, 2611.69 P/B ratio, and 17.24% earnings growth, these metrics solidify its Underperform investment rating.